Companies involved in the development of therapeutic antibodies (as well as other therapeutic proteins) need to choose and develop the right lead as early as possible in order to avoid either technical or IP deadlocks, and to ensure that they are heading in the optimal direction. In addition, it is necessary to file the broadest possible patents as quickly as possible.

Deeptope’s offer consists in characterizing antigen/antibody interactions (epitope/paratope mapping) and optimizing antibodies. The company can also work on many other protein-protein interactions and corresponding protein optimizations.

Their methodology is based on the use of high-throughput in vitro mutagenesis data.
In the context of therapeutic protein development, Deeptope provides:

– Epitope mapping:
• Equally reliable data whether the epitope is conformational or linear
• Economies of scale, with the possibility to use the same antigen mono-mutant library for several antibodies
• A short time frame (4 to 6 weeks)

– Paratope mapping:
• In vitro functional data
• Accuracy to the nearest amino acid
• Comprehensive, reliable, robust and reproducible results
• Prediction of cross-reactivity and selectivity
• A short time frame (4 to 6 weeks)

– Optimization:
• A 360° screening, via the identification of all mutations of interest
• A simultaneous, multi-parametric process that allows the identification of an optimized sequence as well as the associated family of variants (IP protection)
• Fast (4 to 6 weeks), definitive and comprehensive results

Thanks to its services, Deeptope’s clients optimize development costs by derisking their programs at the best cost/duration ratio:

1) Through the evaluation of a large number of leads to choose one according to criteria specific to the biology of the target, freedom to operate, cross-reactivity, selectivity, and other factors

2) By obtaining an optimized lead ready for clinical trials and reinforcing antibody patentability by describing the epitope and paratope and protecting a sequence and a family of associated variants